Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Lilit Karapetyan, MD, MS, FACP

Advertisement

Articles by Lilit Karapetyan, MD, MS, FACP

1 expert is featured in this series.

Real World, Evidence based, retrospective study of patients infused with commercially released Lifileucel for unresectable or metastatic melanoma

ByLilit Karapetyan, MD, MS, FACP
February 12th 2026

Rapid readout of real-world advanced melanoma care reveals treatment patterns, outcomes, and safety insights that complement trial evidence.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on OncLive

    1

    Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma

    2

    ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC

    3

    mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC

    4

    FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors

    5

    Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers

    • Advertise
    • About OncLive
    • Editorial Board
    • MJH Life Sciences brands
    • Contact Us
    • Privacy
    • Terms & Conditions
    • Do Not Sell My Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo
    Download on Apple
    Download on Google Play

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us